Prosonix has submitted an MAA for its PSX1001 fluticasone propionate MDI for the treatment of asthma, triggering a milestone payment from Mylan, the company has announced. In April 2014, Mylan acquired marketing rights for PSX1001 and another FP inhaler, PSX1050, in most of Europe, North America, Japan, Australia, India, and a number of other countries.